RSV, vaccine
RSV Vaccine Shows Strong Protection for Older Adults
A large new study says the RSV vaccine is 80% effective at preventing hospitalization in older adults due to complications from the illness, and works just as well at protecting them from death or needing intensive care unit support for severe complications.
RSV vaccine effective in preventing hospitalizations in older Americans
Today, The Lancet published the first real-world data analysis of respiratory syncytial virus (RSV) vaccine efficacy among older US adults in a large multistate study. The study shows the vaccine was 80% effective in protecting against hospitalizations and deaths during the 2023-2024 RSV season.
Shawn Johnson shares daughter Drew Hazel, 4, and sons Jett James, 2, and Barrett 'Bear' Madison, 10 months, with her husband ...
17hon MSN
(Corrects headline, paragraph 1 and 2 in Oct. 17 story to show the drug reduced medically attended lower respiratory ...
Merck’s investigational antibody clesrovimab demonstrated more than 60% effectiveness in reducing some types of respiratory ...
RSV is a virus that can make people sick, especially older adults and babies. But even though RSV can be serious, people aren ...
New data released by Merck suggests AstraZeneca and Sanofi’s Beyfortus, the monoclonal antibody injection that protects ...
AUSTIN (KXAN) — In 2023, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) ...
WellSpan Ephrata Community Hospital is now offering respiratory syncytial virus immunizations to infants born at the hospital ...
Merck said on Thursday its experimental antibody therapy, clesrovimab, demonstrated a 60.4% effectiveness in reducing some ...
In the study, clesrovimab (MK-1654) significantly reduced the incidence of RSV disease and hospitalisations in healthy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback